Our new start-up Visotec is supported by Bayer’s “G4ADigital Health Partnerships program”

Our new start-up Visotec GmbH will be supported by the Bayer “G4ADigital Health Partnerships program”. Aim of the program is to drive innovative digital health solutions for patients and to establish longer-term collaborations for the development of specific digital health care solutions in a variety of fields including cardiovascular diseases, oncology, ophthalmology, pulmonology, radiology as well as digital therapeutics. The support includes a funding of EUR 75.000.

Eleven start-ups were selected from more than 750 international applications out of 65 countries. Decision was based on the strategic fit and development stage of the proposed projects.

Visotec GmbH develops innovative home-monitoring solution for the treatment of proliferative retina diseases which are currently treated by intravitreal injection of anti-VEGF drugs. These diseases include age related macular degeneration AMD, the leading cause of blindness in the industrialized countries. Due to a lack of adequate monitoring of the disease progression, patients are often over or under treated, resulting in unnecessary cost or non-optimal therapy results. At the Medical Laser Center Lübeck (MLL) a new technology was developed, which allows a cost-effective device for home-monitoring by optical coherence tomography (OCT). Supported by an EXIST Transfer of Research the company Visotec GmbH recently spun off from the (MLL) in cooperation with the Institute of Biomedical Optics (BMO).

Further information: https://media.bayer.de/baynews/baynews.nsf/id/Bayer-vereinbart-Kooperationen-mit-elf-Startups-unter-G4A-Digital-Health-Partnerships-Program  

Close Menu